1. Home
  2. OABI

OABI

OmniAb Inc.

Logo OmniAb Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-18-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Founded: 2012 Country:
United States
United States
Employees: N/A City: EMERYVILLE
Market Cap: 579.8M IPO Year: N/A
Target Price: $9.20 AVG Volume (30 days): 459.4K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.51 EPS Growth: N/A
52 Week Low/High: $3.14 - $6.72 Next Earning Date: 05-09-2024
Revenue: $34,164,000 Revenue Growth: -42.17%
Revenue Growth (this year): -5.21% Revenue Growth (next year): 79.79%

Share on Social Networks: